Evaxion A/S (NASDAQ:EVAX) Issues Quarterly Earnings Results

Evaxion A/S (NASDAQ:EVAX – Get Free Report) posted its earnings results on Thursday. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.49), FiscalAI reports.

Evaxion A/S Price Performance

EVAX opened at $2.54 on Thursday. The business’s 50-day moving average is $3.10 and its two-hundred day moving average is $3.42. Evaxion A/S has a 1 year low of $2.42 and a 1 year high of $6.92. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. The firm has a market capitalization of $22.91 million, a PE ratio of -2.10 and a beta of 0.60.

Analyst Ratings Changes

A number of research firms have recently issued reports on EVAX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research note on Tuesday, October 6th. Wall Street Zen raised shares of Evaxion A/S to a “hold” rating in a report on Saturday, November 14th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

View Our Latest Stock Report on Evaxion A/S

Evaxion A/S Company Profile

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.

Read More

Earnings History for Evaxion A/S (NASDAQ:EVAX)

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.